MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Method for the determination of the rate of mitochondrial respiration and its application to the search for regulators of the uncoupling proteins (UCP)

Consejo Superior de Investigaciones Cientificas, CSIC (Spanish National Research Council)
This procedure allows the monitorization of respiration. This method is useful for identify compounds that regulate the activity of the UCPs. These compunds would be potential drugs to treat obesity or as antipyretic.

Mechanism of action

High throughput screening procedure

Full description

Mitochondria are the cellular organelles where ATP is produced from the energy released during the oxidation of sugars and lipids. This process, termed oxidative phosphorylation, can be divided in two parts: respiration (substrate oxidation) and ATP synthesis. Both are coupled in such way that rate of substrate oxidation is adjusted to cellular demand for ATP synthesis. This coupling has important implications for cellular economy since reserves are not wasted.

However, certain physiological situations require energy dissipation. Maintenance of body temperature is one example: in mammals non- shivering thermogenesis is achieved by uncoupling oxidative phosphorylation. This mechanism is also used to eliminate excess calories ingested with the diet. Energy dissipation is important to lower the rate of free radical production, these reactive species cause cell damage that can eventually lead to cell death. The proteins that catalyse this energy dissipation are termed uncoupling proteins (UCP).

We have developed a procedure to determine the rate of mitochondrial respiration, applicable to evaluate the ability of compounds to modulate the activity of the UCP, since changes in UCP activity necessarily lead to changes in the rate of mitochondrial respiration . This compounds could become potential drugs for treating diseases due to changes in thermogenic activity of tissues where these proteins are present  (diabetes, hypertension, cachexia).

INNOVATIVE ASPECTS

The method is a high throughput screening procedure that presents important advantages compared to existing protocols. Identification of new therapeutic compounds (obesity, diabetes, development of new antipyretics, etc.) with this method is easy, cheap, highly reproducible and useful to process high number of samples.

COMPETITIVE ADVANTAGES

This procedure is highly suitable to screen a large number of compounds.

Development status

Early Stage

Type of business relationship sought

Research under contract or research collaboration

Licensing contact

Dr Jose Pablo Zamorano
Area Coordinator - Life Sciences
IP Commercialization

Contact directly

Company details

Consejo Superior de Investigaciones Cientificas, CSIC (Spanish National Research Council)

Spanish public research organisation with 126 centres covering all knowledge areas and highly active in collaborating with the industry.

View profile

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
BioTrinity
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us